These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31548012)

  • 1. Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.
    Kumru OS; Saleh-Birdjandi S; Antunez LR; Sayeed E; Robinson D; van den Worm S; Diemer GS; Perez W; Caposio P; Früh K; Joshi SB; Volkin DB
    Vaccine; 2019 Oct; 37(44):6696-6706. PubMed ID: 31548012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine.
    Khan MDFH; Youssef M; Nesdoly S; Kamen AA
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of stable liquid formulations for adenovirus-based vaccines.
    Evans RK; Nawrocki DK; Isopi LA; Williams DM; Casimiro DR; Chin S; Chen M; Zhu DM; Shiver JW; Volkin DB
    J Pharm Sci; 2004 Oct; 93(10):2458-75. PubMed ID: 15349956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Mechanism of Glass Delamination in Type 1A Borosilicate Vials Containing Frozen Protein Formulations.
    Jiang G; Goss M; Li G; Jing W; Shen H; Fujimori K; Le L; Wong L; Wen ZQ; Nashed-Samuel Y; Riker K; Germansderfer A; Tsang P; Ricci M
    PDA J Pharm Sci Technol; 2013; 67(4):323-35. PubMed ID: 23872443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical Characterization and Stabilization of a Lentiviral Vector Against Adsorption and Freeze-Thaw.
    Kumru OS; Wang Y; Gombotz CWR; Kelley-Clarke B; Cieplak W; Kim T; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Nov; 107(11):2764-2774. PubMed ID: 30017889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate.
    Patel A; Erb SM; Strange L; Shukla RS; Kumru OS; Smith L; Nelson P; Joshi SB; Livengood JA; Volkin DB
    Vaccine; 2018 May; 36(22):3169-3179. PubMed ID: 28506515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiny steps towards an HIV vaccine.
    Willyard C
    Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines.
    Wiggan O; Livengood JA; Silengo SJ; Kinney RM; Osorio JE; Huang CY; Stinchcomb DT
    Vaccine; 2011 Oct; 29(43):7456-62. PubMed ID: 21803103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.
    Agarwal S; Sahni N; Hickey JM; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):394-406. PubMed ID: 31400346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of freeze/thaw-related quality attributes of a liquid biopharmaceutical formulation: the role of saccharide excipients.
    Zhou R; Schlam RF; Yin S; Gandhi RB; Adams ML
    PDA J Pharm Sci Technol; 2012; 66(3):221-35. PubMed ID: 22634588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.
    Kumar P; Shukla RS; Patel A; Pullagurla SR; Bird C; Ogun O; Kumru OS; Hamidi A; Hoeksema F; Yallop C; Bines JE; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2021 Jul; 17(7):2298-2310. PubMed ID: 33861183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation of excipients for a stable Orf viral vector formulation.
    Eilts F; Harsy YMJ; Lothert K; Pagallies F; Amann R; Wolff MW
    Virus Res; 2023 Oct; 336():199213. PubMed ID: 37657509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poxvirus vector-based HIV vaccines.
    Pantaleo G; Esteban M; Jacobs B; Tartaglia J
    Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.
    Donnelly L; Curran RM; Tregoning JS; McKay PF; Cole T; Morrow RJ; Kett VL; Andrews GP; Woolfson AD; Malcolm RK; Shattock RJ
    Vaccine; 2011 Jun; 29(27):4512-20. PubMed ID: 21514349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for improved stability of Peste des Petits Ruminants Vaccine.
    Silva AC; Carrondo MJ; Alves PM
    Vaccine; 2011 Jul; 29(31):4983-91. PubMed ID: 21570436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates.
    Takahashi MN; Rolling JA; Owen KE
    Virol J; 2010 Feb; 7():39. PubMed ID: 20163742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of replication-competent viral vectors for HIV vaccine delivery.
    Parks CL; Picker LJ; King CR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):402-11. PubMed ID: 23925000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectoine and Hydroxyectoine Stabilize Antibodies in Spray-Dried Formulations at Elevated Temperature and during a Freeze/Thaw Process.
    Nayak PK; Goode M; Chang DP; Rajagopal K
    Mol Pharm; 2020 Sep; 17(9):3291-3297. PubMed ID: 32672979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Freeze/thaw of IGG solutions.
    Horn J; Jena S; Aksan A; Friess W
    Eur J Pharm Biopharm; 2019 Jan; 134():185-189. PubMed ID: 30529434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.